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Original Article
Abstract
Purpose: Contemporary literature on lung adenocarcinoma has demonstrated a genetic difference of the epidermal growth fac-
tor receptor (EGFR) pathway conferring to ethnicity, such as higher frequency of activated EGFR mutations in East Asian pop-
ulation. This information is missing in some developing countries, and we intend to address this gap in the literature. Methods:
We examined the rate of EGFR mutations among Pakistani patients with adenocarcinoma of the lung. Fine-needle aspiration
samples were gathered from 73 patients. Polymerase chain reaction was performed on extracted DNA for mutational analysis of
EGFR exons 19 and 21. Results: EGFR mutations were discovered in 18 of 73 (24.6%) patients. We did not find any significant
difference in EGFR mutation rate with regard to patient's age, sex, smoking history, clinical stage of lung cancer, subtypes of
adenocarcinoma, and tumor differentiation. Conclusion: Our investigation shows that the EGFR mutation rate in our patient
population with adenocarcinoma of the lung was higher than in African-American, Arabian, and white Caucasian patients, and
was lower than the East Asian population.
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Introduction
The rate of epidermal growth factor receptor (EGFR) muta-
tion in non-small cell lung cancer is known to vary
throughout ethnic groups, with nearly 10% of patients with
non-small cell lung cancer (NSCLC) in the US and 35% in
East Asia have tumor associated EGFR mutations.1-4 These
mutations occur within EGFR exons 18-21, which encodes a
percentage of the EGFR kinase domain. About 90% of the
mutations are exon 19 deletions or exon 21 L858R point mu-
tations.5 The influence of ethnicity on the rate of the muta-
tion is poorly understood.
Contemporary literature suggests that EGFR mutations offer
survival benefit independent of therapy.6, 7 Literature con-
centrating on East Asian population indicates that the inci-
dence of classical EGFR mutations is predictive of survival
benefit following EGFR tyrosine kinase inhibitor (TKI)
therapy.8
After a meticulous review of the literature, we did not find
any reports of genetic backgrounds of lung cancer in Paki-
stan. Therefore, we studied the rate of major types of acti-
vating mutations in exons 19 and 21 of EGFR in Pakistani
patients with adenocarcinoma of the lung.
Methods and Materials
Seventy-three patients underwent computed tomography
(CT)-guided fine-needle aspiration (FNA) biopsy at the Ka-
rachi Institute of Radiotherapy and Nuclear Medicine
(KIRAN), and Atomic Energy Medical Centre (AEMC) at
Jinnah Post Graduate Medical Centre (JPMC) Karachi from
2011 to 2013. The study complies with the institutional re-
view board committee policies. Informed consents were
obtained from all participants.
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None of the study participants were exposed to chemother-
apy prior to FNA. All pathological diagnoses were conducted
by pathologist’s blind to the clinical information, and veri-
fied by one pathologist in accordance with the WHO classi-
fication system.
FNA and DNA samples
Tumor specimen was obtained using the approved protocols
of the IRB through CT-guided FNA biopsies using 23-gauge
needles in all participants. Appropriateness for DNA extrac-
tion was documented after pathologists confirmed more than
70% tumor cells in each sample.
FNA samples were instantly stored in tubes containing
99.5% ethanol at -80°C. Genomic DNA was isolated from
tissue by removal of ethanol after high-speed centrifugation.
A modified procedure using the commercial DNAzol reagent
was successfully applied to extract genomic DNA (DNAzol®
BD, Molecular Research Center, Cincinnati, USA).
Polymerase chain reaction single-strand conformation pol-
ymorphism was utilized to identify mutations in exons 19
and 21 of the EGFR gene. PCR was done by the AmpliTaq
Gold PCR Master Mix (Life Technologies, USA). Table 1
illustrates the primers and PCR conditions used. After dena-
turing PCR products, electrophoresis was done with the
GenePhor System and GeneGel Excel 12.5/24 (GE
Healthcare, Sweden) at 18°C, 650 V for 80 minutes. The gels
were stained using the DNA Silver Staining Kit (Promega,
Madison, WI, USA).
TABLE 1: Association of EGFR gene mutations to clinicopathological features.
Variable Total patients(n=73)
EGFR gene mutation status
Mutated Wild-type P-value
(n=18) (n=55)
Age, median (range) 58.9(18–84) 61.6 (43-79) 56.2 (18-84)
<60 years of age 47 8 (17%) 39 0.12
≥60 years of age 26 10 (38.4%) 16
Gender 0.39
Male 53 14 (26.4%) 39
Female 20 4 (20%) 16
Smoking status 0.95
Never-smoker 27 7 (26%) 20
Former-smoker 12 4 (33.3%) 8
Current-smoker 34 7 (20.5%) 27
Clinical stage 0.46
Stage I 10 4 (40%) 6
Stage II 20 6 (30%) 14
Stage III 18 3 (16.6%) 15
Stage IV 25 5 (20%) 20
Subtypes of adenocarcinoma 0.63
Bronchio-alveolar 2 0 2
Papillary 4 0 4
Solid 2 0 2
Mixed 65 18 47
Acinar component 0.54
Present 41 8 (19.5%) 33
Absent 32 7 (21.8%) 25
Bronchio-alveolar component 0.87
Present 14 2 (14.2%) 12
Absent 59 13 (22%) 46
Papillary component 0.05
Present 37 6 (16.2%) 31
Absent 36 12 (33.3%) 24
Solid component 0.23
Present 16 3 (18.7%) 13
Absent 57 15 (26.3%) 42
Tumor differentiation 0.23
Well 9 2 (22.2%) 7
Moderate 24 5 (20.8%) 19
Poor 40 14 (35%) 26
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TABLE 2: PCR primers and parameters.
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FIG. 1: Adenocarcinoma of the lung.
Statistical analysis
The incidence of EGFR mutation status along with the cor-
responding important predictors of incidence of EGFR muta-
tions were additionally identified by logistic regression with
a forward-model selection procedure. The factors included in
the model selection were age, sex, histology, and stage of the
tumor. Continuous measurements between two groups were
examined by the t test or Fisher’s exact test, whereas, the
Mann-Whitney U test determined the differences between
the continuous variables. All tests were two-sided. A p-value
< 0.05 was considered statistically significant.
Results
Of the 73 tumor patients, mutations in exons 19 and 21 of
the EGFR gene were detected in 11 (15%) and 7 (9.5%) tu-
mors. Estimated mutation rate was 24.6% (18 of 73). Muta-
tion male to female rate was 26.4 % (14 of 53) and 20% (4 of
20) Table 1. Table 2 reviews the association of EGFR gene
mutations to clinicopathological features. A higher incidence
of EGFR mutation was appreciated in adenocarcinomas with
papillary component (0.05). We did not find any other sig-
nificant relationship between EGFR mutation rate and pa-
tient characteristics.
Discussion
According to our literature search, our study is the only re-
port available comprising information on EGFR mutations in
a Pakistani patient population. Considering that our recruit-
ing site is one of the principal cancer centers in the country,
it is likely that our findings closely reflect the overall occur-
rence of EGFR mutations in the population of Pakistan.
Our study shows that the EGFR mutation rate in Pakistani
patients with adenocarcinoma of the lung was higher than
the African-American9, Arabian10, and white Caucasian pa-
tients1, 2, and was lower than in patients in East Asia and
other countries of South Asia.11-13 This is probably the result
of the fundamental differences between cohorts.
It is worth mentioning that a latent tumor stage at diagnosis
may have affected the reported ethnic disparity in EGRF
mutation rate, since Pakistan has no mandatory national
health insurance policy yet, and therefore, Pakistani patients
often present at advanced stages of the lung cancer [Figure
1].
While our sample size is not sufficient to draw any conclu-
sion, our results however may predict a higher likelihood of
important responses to EGFR-TKIs in Pakistani patients with
adenocarcinoma of the lung than in African–American, Ara-
bian, and white Caucasian patients. This hypothesis is par-
ticularly of interest for patients in Pakistan, where lung can-
cer cases are diagnosed at advanced stages and surgery is no
longer a therapeutic option. Additionally, the conclusions of
our study may benefit future prospective clinical trials in-
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crease the number of patients to fully investigate the rela-
tionship between the presence of activating EGFR mutation
and response to TKIs.
Conclusion
Epidermal growth factor receptor mutations were found in
18 of 73 (24.6%) Pakistani patients. Our investigation shows
that the EGFR mutation rate in our patient population with
adenocarcinoma of the lung was higher than in Afri-
can-American, Arabian, and white Caucasian patients, and
was lower than the East Asian population.
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